Servier Pipeline

January 2025

SERVIER
moved by you

Oncology – solid tumors

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
Vorasidenib	S95032	Solid tumors	Worldwide	PCD 1 2 3	
Ivosidenib	S95031	Solid tumors (new indication)	Worldwide	PCD 1 2 3	
Vorasidenib + temozolomide	S95032	Solid tumors	Worldwide	PCD 1 2 3	
Vorasidenib + pembrolizumab	S95032	Solid tumors	Worldwide	PCD 1/2 3	
Ivosidenib combo	S95031	Solid tumors (new indication)	Worldwide	PCD 1/2 3	
Anti-TIM3 combo	S95018	Non-small Cell Lung Cancer	Worldwide	PCD 1/2 3	
Anti-CD73 combo	S95024	Non-small Cell Lung Cancer	Worldwide	PCD 1/2 3	
Anti-NKG2A combo	S95029	Non-small Cell Lung Cancer and Gastric cancer	Worldwide	PCD 1/2 3	
MAT2A inhibitor	S95035	Solid tumors	Worldwide	PCD 1 2 3	
ND	S95043	Solid tumors	Worldwide	PCD 1 2 3	

Data as of January 2025

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action, ND= Not disclosed

Oncology – Hematological malignancies

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
Ivosidenib combo 7+3 (chemo)	S95031	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	
Ivosidenib	S95031	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	
Calaspargase pegol combo	S95015	Hematological malignancies (new indication)	Worldwide	PCD 1 2 3	
Cemacabtagene ansegedleucel (Cema-Cel) Anti-CD19 Allogeneic CAR-T*	S95023*	Diffuse Large B-Cell Lymphoma	Licensed from Cellectis and Sub-Licensed to Allogene*	PCD 1 2 3	
ADC CD74-Mcl1 inihibitor + Venetoclax	S227928	R/R Acute Myeloid Leukemia and R/R Chronic Myelomonocytic Leukemia	Worldwide	PCD 1 2 3	Vernalis

Data as of January 2025

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action, ND= Not disclosed
R/R = Relapsed/Refractory

*Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene, the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.

Neurology and immuno-inflammation

NEUROLOGY

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
LRRK2 inhibitor	S221237	Parkinson's disease	Worldwide	PCD 1 2 3	OPM Oncodesign Precision Medicine
ND	S230815	Neurodevelopmental disorder	Worldwide	PCD 1 2 3	

IMMUNO-INFLAMMATION

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
ND	S95041	Autoimmune disease	Worldwide	PCD 1 2 3	
ND	S95042	Autoimmune disease	Worldwide	PCD 1 2 3	
ND	S95044	Autoimmune disease	Worldwide	PCD 1 2 3	

Data as of January 2025

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action, ND= Not disclosed